Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Rheumatoid Arthritis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Rheumatoid Arthritis
    TopAbstracts in Rheumatoid Arthritis 10/02/2008 - (DGNews)
    Dose Adjustment Not Necessary in Patients With Rheumatoid Arthritis Treated With TRU-015: Presented at ACCP - (DGDispatch)
    Monitoring of Methotrexate Toxicity Needed When Etoricoxib Is Added to Methotrexate in Rheumatoid Arthritis: Presented at ACCP - (DGDispatch)
    TopAbstracts in Rheumatoid Arthritis 09/18/2008 - (DGNews)
    Golimumab Pharmacokinetics Determined in Patients With Rheumatoid Arthritis: Presented at ACCP - (DGDispatch)

    News archive

     Recent webcasts/CME - Rheumatoid Arthritis
    • Beyond Efficacy and Safety in Rheumatoid Arthritis Treatment: Quality-of-Life Outcomes With Newer Biologics in RA
    • Hepatic Effects of Biologic Agents: Current and Future Issues in the Treatment of Rheumatoid Arthritis
      Cardiovascular Disease in Patients With Rheumatoid Arthritis: Results From the QUEST-RA Study
      Pathology and Treatment of Rheumatoid Arthritis: The Role of IL-6 in Inflammation and Rheumatoid Arthritis
      Systemic Pathology of Rheumatoid Arthritis

      Webcasts/CME archive

       Recent cases - Rheumatoid Arthritis
        Disseminated Cutaneous Herpes Simplex Virus-1 in a Patient with Rheumatoid Arthritis Receiving Infliximab: A Case Report
        Rheumatoid Nodule of the Thyrohyoid Membrane: A Case Report
        Recurrent Pneumothorax in a Patient with Rheumatoid Arthritis on Leflunomide Treatment: Case Report and Overview of the Literature
        Spontaneous Esophageal Perforation in a Patient with Achalasia Cardia and Rheumatoid Arthritis
        Rheumatoid Arthritis in Thalassemia Intermedia: Coincidence or Association?

        Cases archive
          




        my personal edition > rheumatoid arthritis > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Infliximab May Induce Antinuclear Antibodies

        A DGReview of :"Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy"
        Arthritis & Rheumatism

        05/12/2003
        By David Loshak


        The monoclonal antibody infliximab may induce antinuclear antibodies -- especially IgM and IgA anti-double stranded DNA antibodies -- in patients with rheumatoid arthritis and spondyloarthropathy, according to research conducted at Ghent University Hospital, Belgium.

        The study showed no anti-double stranded DNA IgG antibodies and signs or symptoms of lupus over the 30-34 weeks of infliximab treatment.

        However, the researchers emphasise, further follow-up is essential because their findings did not exclude potential long-term induction of clinically significant lupus.

        They investigated the effect of infliximab on antinuclear antibodies, anti-double-stranded DNA, antinucleosome, antihistone and anti-extractable nuclear antigen antibodies in 62 patients with rheumatoid arthritis and 35 with spondyloarthropathy. All were tested at baseline and at week 30 (rheumatoid arthritis) or week 34 (spondyloarthropathy).

        Initially, 32 of the rheumatoid arthritis patients tested positive for antinuclear antibodies but after infliximab treatment 51 patients tested positive (P<0.001). Likewise, the number of spondyloarthropathy patients testing positive increased from six at baseline to 31 at 34-week follow-up (P<0.001).

        At baseline, no patient in either group had anti-double stranded DNA antibodies, but after infliximab treatment, seven rheumatoid arthritis patients and six spondyloarthropathy patients tested positive(P=0.016 and P=0.031 respectively).

        All seven rheumatoid arthritis patients who were positive for anti-double stranded DNA had IgM and IgA anti-double stranded DNA antibodies. In the spondyloarthropathy group, that number, three of six had IgM and IgA anti-double stranded DNA antibodies, and two had IgM anti-double stranded DNA antibodies alone.

        In both groups, the IgM anti-double stranded DNA antibodies appeared before the IgA anti-double stranded DNA antibodies.

        Although some patients who were treated with infliximab developed antibodies to antinucleosome, antihistone and anti-ENA, the numbers were not statistically significant, the researchers note.
        Arthritis Rheum 2003 Apr;48:4:1015-23. "Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send